Andrew D Huber

12PUBLICATIONS

23CO-AUTHORS

PharmacogenomicsReaction engineering (excl. nuclear reactions)Wastewater treatment processesMolecular targetsCheminformatics and quantitative structure-activity relationships

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jun 23, 2026

Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.

|Nov 06, 2025

PROTAC repurposing uncovers a noncanonical binding surface that mediates chemical degradation of nuclear receptors.

Andrew D Huber, Wenwei Lin, Young-Hwan Jung

|Nov 27, 2024

Addition/Correction to "First-in-Class Small Molecule Degrader of Pregnane X Receptor Enhances Chemotherapy Efficacy".

Andrew D Huber, Young-Hwan Jung, Yongtao Li

|Oct 15, 2024

First-in-Class Small Molecule Degrader of Pregnane X Receptor Enhances Chemotherapy Efficacy.

Andrew D Huber, Young-Hwan Jung, Yongtao Li

|Aug 19, 2024

A new mode of inhibition.

Andrew D Huber, Taosheng Chen

|May 14, 2024

Chemical manipulation of an activation/inhibition switch in the nuclear receptor PXR.

Efren Garcia-Maldonado, Andrew D Huber, Sergio C Chai

Pageof 2

Frequent Collaborators

Taosheng Chen

Wenwei Lin

Philip R Tedbury

Sergio C Chai

Anthony A High

Zhengqiang Wang

Stefan G Sarafianos

Eleftherios Michailidis

1 joint publications

Robert Ralston

1 joint publications

Stanley Nithianantham

Frequent Collaborators

Taosheng Chen

Wenwei Lin

Philip R Tedbury

Sergio C Chai